1 / 33

Osteosarcoma

Development of HLA-A2- and HLA-A24-restricted peptide vaccines from a novel osteosarcoma antigen, papillomavirus binding factor. S Kawaguchi, T Tsukahara, T Wada, S Nagoya, M Kaya, T Torigoe, N Sato, T Ishii, S Tatezaki, T Yamashita Sapporo Medical University, Chiba Cancer Center Hospital.

alaric
Download Presentation

Osteosarcoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Development of HLA-A2- and HLA-A24-restricted peptide vaccines from a novel osteosarcoma antigen, papillomavirus binding factor S Kawaguchi, T Tsukahara, T Wada, S Nagoya, M Kaya, T Torigoe, N Sato, T Ishii, S Tatezaki, T Yamashita Sapporo Medical University, Chiba Cancer Center Hospital

  2. Osteosarcoma Introduced by Alexis Boyer in 1814.

  3. Immunotherapy for osteosarcoma Campbell CJ, Cohen J, Enneking WF: New therapies for osteogenic sarcoma. J Bone Joint Surg Am 57:143-144, 1975. - Immunotherapy - Methotrexate - Adriamycin

  4. Autologous tumor cell vaccination as adjuvant therapy Amputation Marcove et al, CA, 1973

  5. Current immunotherapy Antigenic peptide TCR T cell Tumor cell Vaccination

  6. T cell T cell T cell Active immunotherapy (vaccination) Patients Peptide vaccines Injection T cell T cell Dendritic cell T cell T cell T cell T cell T cell T cell T cell Tumor cell

  7. Peptide vaccination for malignant melanoma MAGE-3 Coulie PG, Universite de Louvain ,Brussels

  8. Goal Efficacious peptide vaccines for Osteosarcoma

  9. To identify tumor antigens and antigenic peptides T cell TCR HLA class I Tumor

  10. 16 y.o. F, Osteosarcoma OS2000 TcOScl-303

  11. TcOScl-303 kills OS2000, but not 293EBNA or K562 cells OS2000 IFN-γ(+) OS2000 + TcOScl-303 OS2000 IFN-γ(-) ▲293EBNA K562 3 50 16 E/T ratio Nabeta et al., J Orthop Sci, 2003.

  12. Cloning of a gene encoding the antigenic peptide TcOScl-303 TCR HLA class I OS2000 Expression cloning Antigenic peptide

  13. Papillomavirus Binding Factor (PBF) as a novel osteosarcoma antigen PBF Open reading frame Zn finger 5' 337 1878 ↑ 5' UTR Clone 1B9.1H4 ΔN-PBF 704 ↑ 3' UTR (432bps) • Protein that binds to the E2 binding site of human • papillomavirus type 8 Boeckle et al., Virology, 2002

  14. Osteosarcoma Pancreas Ovary Spleen Anti- PBF Immunostaining with anti-PBF antibody Osteosarcoma 72/78 Ewing’s sarcoma 31/34 Synovial sarcoma 18/20 Tsukahara et al., Cancer Res, 2004

  15. Stages of PBF Project I II III IV Identification Function Regulation Application Boeckle et al., 2002 Tsukahara et al., 2004

  16. Stages of PBF Project I II III IV Identification Function Regulation Application Boeckle et al., 2002 Tsukahara et al., 2004 Prognostic significance, Targeting/Overexpression Associated proteins, Expression of HLA class I Development of peptide vaccines

  17. Event-free Survival of OS Pts. PBF negative: 6 P=0.025 PBF positive: 72 Tsukahara et al., Cancer Sci, 2008

  18. Stages of PBF Project I II III IV Identification Function Regulation Application Boeckle et al., 2002 Tsukahara et al., 2004 Prognostic significance, Targeting/Overexpression Associated proteins, Expression of HLA class I Development of peptide vaccines

  19. PBF knock-out mice PBF (+/-)

  20. Stages of PBF Project I II III IV Identification Function Regulation Application Boeckle et al., 2002 Tsukahara et al., 2004 Prognostic significance, Targeting/Overexpression Associated proteins, Expression of HLA class I Development of peptide vaccines

  21. Bait : PBF Yeast Two-hybrid Screening Yeast Prey : cDNA library of OS2000

  22. open reading frame 1126 5’ 3’ Ubiquitin-like domain NLS (1030-1053) HLA-B Associated Transcript 3 (BAT3) OS2000 PBF BAT3 Merge Tsukahara et al., Cancer Sci, 2009

  23. Stages of PBF Project I II III IV Identification Function Regulation Application Boeckle et al., 2002 Tsukahara et al., 2004 Prognostic significance, Targeting/Overexpression Associated proteins, Expression of HLA class I Development of peptide vaccines

  24. PBF TcOScl-303 TCR HLA-B55 OS2000 16 y.o. F HLA in Japanese population B55 A24 B61 A2 B51 HLA-restriction and HLA-limitation

  25. PBF-peptides w/ HLA-24 binding motif PBF

  26. Binding Affinity to HLA-A24 AYRPVSRNI

  27. Frequency of T cells in patients with OS, reacting with the A24.2 peptide Participants Age Status of Chemotherapy Frequency tumor bearing among CD8+ cells -6 (P) , M 7 x 10 1 18 underway -7 6 x 10 2 42 P not done -6 6 x 10 3 8 (P) underway -7 5 x 10 4 12 (P) underway -6 < 1 x 10 5 65 (P), M underway 2 x 10 6 20 (P) underway -6 6 x 10 7 16 (P) underway -6 3 x 10 8 12 (P) underway -6 3 x 10 9 20 P underway -6 9 x 10 10 18 P done -7 Average: 3.2 x10-6

  28. 20.2% OS2000 OS2000+IFNγ LCL-OS2000 HOS U2OS K562 CTL #034 Cytotoxicity of anti-A24.2 CTLs Tsukahara et al., Cancer Sci, 2008 Tsukahara et al., J Transl Med, 2009

  29. A2.2 ALPSFQIPV 2009 Approved Delivered PBF-derived peptide vaccines HLA-A24 HLA-A2 Peptide A24.2 Sequence AYRPVSRNI Publication IRB GMP grade peptide 2008 Approved Delivered

  30. Case Age Peptide Vaccination Immune response 1 18 A24.2 2 ND 2 16 A2.2 2 ND 10w 11w 1w 2w 3w 4w 5w 6w 7w 8w 9w 12w Peptide + IFA 2nd 3rd 4th 5th 1st 6th Toxicity Tumor - PD - PD Vaccination Protocol Peptide (1mg) + IFA (Montanide ISA 51)

  31. A giant step forward – If…. For many years osteogenic sarcoma has been the “bete noire” of the chemotherapeutist. Burchenal JH, New Engl J Med:1974

  32. A clue 1970s High-dose MTX Rosen G 2000s High-dose Rosenberg SA cell transfer

  33. Conclusion • In the staged translational research, we found that papillomavirus binding factor (PBF) serves as a novel antigen, a poor prognostic factor, and an apoptosis regulator with BAT3, of osteosarcoma. • PBF-derived peptides were recognized by peripheral T cells of patients with osteosarcoma and they induced specific cytotoxicity. • Safety and efficacy of PBF-derived peptide vaccines are currently in clinical evaluation.

More Related